Company / Operating Cash Flow
Insight Molecular Diagnostics Inc. Operating Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$20.7M
FY2025
5-year range
-$45.6M / -$20.7M
FY2021-FY2025
Trend
+11.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$46M to -$21M over the past 2 years.
Based on SEC 10-K filings.
-$21M in FY2025.
Improved from -$46M to -$21M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 11.3% year-over-year.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$20.7M | +11.3% |
| FY2024 | -$23.3M | +48.8% |
| FY2023 | -$45.6M | -26.8% |
| FY2022 | -$35.9M | -38.3% |
| FY2021 | -$26.0M | -31.8% |
| FY2020 | -$19.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026